Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Randox Launches Three New ELISA Kits for the Detection of Z Drugs

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
ELISA kits for the detection of Zopiclone, Zaleplon and Zolpidem in urine and blood specimens.

Randox Toxicology has launched three new ELISA testing kits for the detection of sedative drugs Zopiclone, Zaleplon and Zolpidem.

These drugs behave in a similar ways to benzodiazepines, a psychoactive drug which was traditionally used for the treatment of anxiety or insomnia.

The Z drugs are found in prescription medications; Lunesta, Ambien and Sonata, however they should only be used for a short time period as extended use can lead to tolerance.

The misuse of Z drugs is widespread as a result of both dependence and recreational use. Despite medical advice, many people continue to take these drugs for longer periods than their intended usage; leading to a potential over-dose and hazardous consequences.

Incidents of unusual or inappropriate behaviour have been linked to misuse of Z drugs, were the patient had no memory of their actions.

Some users have reported sleepwalking, sleep driving, binge eating, and performing other daily tasks while asleep. These side effects are troubling in a society were sleeping pills have boomed in popularity.

Randox Toxicology has developed three ELISA kits for the detection of Z drugs in urine and blood specimens.

The Zolpidem ELISA offers an unbeatable Limit of Detection (LOD) of 0.4ng/ml in urine and 0.52ng/ml in blood.

The Zopiclone and Zaleplon ELISA kits are the first immunoassays available for the rapid detection of these drugs. Prior to this, the only way to detect Zopiclone and Zaleplon was with timely chromatographic analysis.

Randox Toxicology also provides an automated ELISA plate reader, capable of reading 96 wells in 30 seconds.

In addition to the Z drug ELISA kits, Randox Toxicology provide a multiplex Biochip Array which targets Zolpidem, Zopiclone, Zaleplon and their metabolites simultaneously from a single, undivided specimen.

The advanced multiplex method consolidates ELISA tests onto a small 9x9mm biochip; enhancing the ability for toxicologists to quickly detect these sedatives.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos